Pricing Log in Create free account
Saturday 17 October 2026 Export LEGN’s income statement to Excel — free account

Legend Biotech Corporation Sponsored ADR

LEGN Healthcare Biotechnology

Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024. In the quarter to June 2026, revenue grew 51.9%, EPS grew 126.1%, free cash flow fell 26.8% and total debt fell 49.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

18.48 1.32 −6.67%
Market cap
$3.8B
P/E
0.0×
Fwd P/E
112×
Dividend yield
—
F-score
3/9
Altman Z
4.54
Beneish M
−2.08
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.57
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — 1 — — 2 — — 2 —
Insider Ownership 1.18%

Capital & Financial Ratios $m

Market Cap 3,840.00
Revenue 1,271.40
Net Income (56.20)
Free Cash Flow (121.80)
Net Debt (808.20)
Current Ratio 3.04 (at or above 1.5: strong)
Debt/Equity 0.13 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E 112.00 (above 35: high)
P/S ratio 2.72
P/B ratio 2.81
Past 5Y EPS Growth —
This Y EPS Growth 94.69% (at or above 15%: strong)
Next Y EPS Growth 1,357.95% (at or above 15%: strong)
Next Y revenue growth 39.76% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.2×, against a ten-year median of 42.5×; over the ten years it ranged from 2.2× in 2026 to 92.1× in 2023.
P/S against its own 10 years 0.50%
10-year low 10-year high
P/B against its own 10 years 0.51%
10-year low 10-year high
EV/Sales against its own 10 years 0.50%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,309 1,123 949 965
Receivables 100 6 13 —
Inventory 19 24 32 42
Other — — — —
1,498 1,284 1,247 1,227
2023 2024 2025 Q'26
Payables 31 39 83 77
ST’ Debt — — 319 156
Other 53 47 12 2
216 278 636 404

Compound Annual Growth %

10y 5y 3y
Sales — 65.93% 106.41%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 29.02% 10.42%

Revenue $m

Mar Jun Sep Dec Year
’26 305 388 — — —
’25 195 255 272 306 1,029
’24 94 — 160 187 627
’23 36 73 96 — 285
’22 42 12 27 — 117
’21 14 22 17 15 69
’20 14 13 13 42 82
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (85) (21) — — —
’25 (104) (13) 29 (12) (100)
’24 16 (2) (76) (82) (144)
’23 (139) (98) (298) — (393)
’22 (79) — (152) — (201)
’21 (27) (58) (45) (70) (198)
’20 (46) (57) (64) (56) (223)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (93) (28) — — —
’25 (106) (22) 24 (25) (129)
’24 9 (5) (78) (84) (158)
’23 (143) (104) (314) — (416)
’22 (91) — (152) — (224)
’21 (44) (58) (45) (115) (244)
’20 (61) (57) (64) (106) (273)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.29) 0.17 — — —
’25 (0.55) (0.68) (0.21) (0.16) (1.61)
’24 (0.33) — (0.68) 0.14 (0.97)
’23 (0.68) (1.14) (0.34) — (2.94)
’22 (0.27) (1.25) (0.52) — (2.81)
’21 (0.61) (0.66) (0.86) (0.74) (2.87)
’20 (0.44) (1.25) (0.50) (0.37) (2.57)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 24.64 23.41 30.76 42.91 32.08 21.19

Analyst estimates 2026–2028

Powerpack
High — — — — 43.24 58.00 57.67 77.32 70.13 45.30
People
People Employees — — — 650 882 1,071 1,390 1,800 2,609 2,965
Revenue/emp, $m — 0.00 0.00 0.10 0.09 0.06 0.08 0.16 0.24 0.35
Income, $m
Income, $m Revenue — 24 63 64 82 69 117 285 627 1,029
Gross margin, % — 0.00 100.00 100.00 100.00 100.00 44.14 49.42 62.60 60.34
EBT — 14 (2) (130) (308) (407) (446) (520) (158) (283)
EBT margin, % — 58.65 (2.56) (202.47) (376.09) (591.63) (380.94) (182.41) (25.20) (27.47)
Net income — 0 (2) (130) (308) (407) (446) (520) (158) (283)
Depreciation — 0 2 5 10 14 18 20 21 29
Per share, $
Per share, $ Revenue — 0.15 0.63 0.64 0.69 0.49 0.74 1.62 3.43 5.58
Earnings — 0.04 (0.03) (1.33) (2.57) (2.87) (2.81) (2.94) (0.97) (1.61)
Cash flow — (0.02) 3.08 (0.83) (1.89) (1.41) (1.27) (2.23) (0.79) (0.54)
Capex — 0.00 (0.21) (0.39) (0.42) (0.32) (0.14) (0.13) (0.08) (0.16)
Free cash flow — (0.02) 2.87 (1.22) (2.31) (1.73) (1.41) (2.36) (0.86) (0.70)
Book value — 0.08 0.09 (1.23) 2.37 5.44 4.68 7.11 5.69 5.44
Shares, m — 157 100 100 118 141 159 176 183 184
Valuation, ×
Valuation, × P/E — 1.43 3.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — 0.00 0.00 56.44 40.68 95.39 81.88 46.04 11.08 3.89
P/B — 0.00 0.00 0.00 11.87 8.57 10.59 8.57 5.72 4.00
EV/Sales — 0.00 0.00 55.04 34.53 84.31 73.94 41.64 9.56 3.45
EV/FCF — 0.00 0.00 (16.48) (8.25) (17.76) (15.17) (13.39) (32.34) (27.43)
Cash, $m
Cash, $m Operating cash flow — (2) 308 (83) (223) (198) (201) (393) (144) (100)
Capex — (1) (21) (39) (50) (45) (22) (23) (14) (29)
Free cash flow — (2) 287 (122) (273) (244) (224) (416) (158) (129)
Balance, $m
Balance, $m Working capital — 179 168 79 432 721 801 1,281 1,006 611
Total debt — 0 5 6 4 121 265 281 301 319
Net debt — (2) (211) (153) (502) (762) (762) (1,028) (821) (629)
Shareholders’ equity — 12 9 (123) 280 766 744 1,251 1,041 1,002
Returns, %
Returns, % ROA — 2.80 (1.30) (37.10) (60.17) (43.86) (36.43) (32.60) (10.06) (17.44)
ROIC — 0.00 0.00 0.00 0.00 (7,010.37) 0.00 (115.31) (56.37) (50.54)
ROE — 89.19 (26.96) 232.83 (385.65) (77.15) (59.11) (51.94) (15.45) (29.06)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Legend Biotech Corporation Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
DNTH Dianthus Therapeutics, Inc. $4.2B — (loss-making) — (loss-making) +294.30% (above 0%: growing) n/m −105.37% (below 0%: shrinking) 100.00% (8,079.11%) Compare
EWTX Edgewise Therapeutics, Inc. $4.2B — (loss-making) — — n/m −30.24% (below 0%: shrinking) 0.00% 0.00% Compare
ABCL AbCellera Biologics Inc. $4.1B — (loss-making) — (loss-making) −76.29% (below 0%: shrinking) n/m +151.98% (above 0%: growing) 100.00% (1,550.05%) Compare
LEGN Legend Biotech Corporation Sponsored ADR $3.8B — (loss-making) 112× +51.90% (above 0%: growing) n/m −26.79% (below 0%: shrinking) 64.54% 14.37%
TNGX Tango Therapeutics, Inc. $3.8B — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −4.58% (below 0%: shrinking) 0.00% 0.00% Compare
RLAY Relay Therapeutics, Inc. $3.8B — (loss-making) — (loss-making) −95.44% (below 0%: shrinking) n/m +2.13% (above 0%: growing) 100.00% (25,949.71%) Compare
ARQT Arcutis Biotherapeutics, Inc. $3.7B 131× 196× +59.33% (above 0%: growing) n/m +227.96% (above 0%: growing) 91.58% 12.65% Compare
TLX Telix Pharmaceuticals Limited $3.6B — — — — −44.78% (below 0%: shrinking) — — Compare
TARS Tarsus Pharmaceuticals, Inc. $3.5B — (loss-making) — (loss-making) +69.41% (above 0%: growing) n/m +288.08% (above 0%: growing) 93.03% (11.45%) Compare
Median of peers $3.8B — — −8.48% — −1.22% 93.03% (11.45%)

All 614 Biotechnology stocks →

Legend Biotech Corporation Sponsored ADR (LEGN) key facts

  • Strength: Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
  • Legend Biotech Corporation Sponsored ADR (LEGN) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
  • As of October 16, 2026, LEGN traded at $18.48, a market capitalization of $3.8 billion.
  • Return on equity was −29.1% and debt-to-equity 0.13.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 4.54 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Legend Biotech Corporation Sponsored ADR (LEGN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/LEGN · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com